FIELD: biochemistry.
SUBSTANCE: described is an antibody or antigen-binding fragment thereof that specifically bind to the MG4 domain in the beta chain of the protein of complement 5 (C5), wherein the antibody comprises a heavy chain complementarity determining region 1 (CDR1) selected from the group consisting of SEQ ID NOs: 1, 11, 21, 31, 41 and 51, CDR2 a heavy chain selected from the group consisting of SEQ ID NOs: 2, 12, 22, 32, 42 and 52, CDR3 heavy chain SEQ ID NO: 3, CDR1 light chain SEQ ID NO: 4, CDR2 light chain SEQ ID NO: 5 and CDR3 light chain SEQ ID NO: 6. Also described is a monoclonal antibody binding to a human C5 protein, or an antigen-binding fragment thereof, comprising a heavy chain variable region having at least 95% sequence identity with SEQ ID NO: 7, 17, 27, 37, 47 or 57; and a light chain variable region having at least 95% sequence identity with SEQ ID NO: 8. In addition, a monoclonal antibody binding to a human C5 protein or an antigen-binding fragment thereof containing a heavy chain having at least 95% sequence identity with SEQ ID NO: 9, 19, 29, 39, 49 or 59; and a light chain having at least 95% sequence identity with SEQ ID NO: 10. Described is a nucleic acid encoding a monoclonal antibody binding to a human C5 protein, or an antigen-binding fragment thereof comprising a heavy chain variable region having at least 95% sequence identity with SEQ ID NO: 7, 17, 27, 37, 47 or 57; and a light chain variable region having at least 95% sequence identity with SEQ ID NO: 8. Corresponding expression vector and host cell are also described.
EFFECT: pharmaceutical composition is provided for the treatment of diseases caused by component 5 complement comprising any of said antibodies and a suitable method of treatment.
28 cl, 19 dwg, 14 tbl, 11 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODY TO HUMAN CD73 | 2017 |
|
RU2754058C2 |
PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING MALIGNANT TUMOUR | 2016 |
|
RU2714205C2 |
HIV-1 SUBTYPE A P17 PROTEIN ANTIBODIES | 2019 |
|
RU2727673C1 |
ANTIBODY AGAINST HUMAN FN14 | 2019 |
|
RU2787044C2 |
ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES | 2017 |
|
RU2781148C2 |
METHOD FOR OBTAINING A LINE OF HUMANIZED MICE CONTAINING 3974insT INSERTION IN THE mGrin2a GENE (MICE GLUTAMATE [NMDA] RECEPTOR SUBUNIT EPSILON-1), LEADING TO PREMATURE TERMINATION OF TRANSLATION OF THE grin2a PROTEIN | 2021 |
|
RU2764650C1 |
NOVEL ANTI-PD-1 ANTIBODIES | 2016 |
|
RU2729830C2 |
BIOSENSOR SYSTEM FOR FAST DETECTION OF DETERMINED COMPONENTS | 2016 |
|
RU2717658C2 |
UNIVERSAL ANTIBODY-MEDIATED BIOSENSOR | 2016 |
|
RU2746486C2 |
IMMUNO-INDUCING AGENT | 2016 |
|
RU2744843C2 |
Authors
Dates
2018-08-03—Published
2014-02-03—Filed